Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

BACKGROUND: We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy (#NCT02449538). METHODS: Everolimus was administered orally at a daily dose of 10 mg continuously (28-day...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Cancer
Huvudupphovsmän: Kim, Seung Tae, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Kang, Won Ki, Lim, Ho Yeong
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2017
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363054/
https://ncbi.nlm.nih.gov/pubmed/28330462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3196-6
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk